Vendor dossier · Nantong, Jiangsu
Nantong Guangyuan Chemical Co., Ltd.
A Nantong chemical company with the largest review volume in the trade and a purification upgrade that shows plainly in the results.
Journal grade · ranked 11 of 28
1,394 reader reports
on the record
Sort every GGPeps result we hold by date and there is a step in the middle of 2025, when the company upgraded its purification train. The determinations before it are spread across most of the width of the range printed below; the seven since sit in its upper half and stay there. The company confirmed the change in writing at the time, and every determination since has come in inside the vendor’s own stated specification.
Storefront The company sells directly at ggpeps.net. Visit GGPeps → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Twelve independent purity determinations, mean 98.1%, range 97.2 to 99.0%, all inside the stated specification. The seven since the purification upgrade sit in the upper half of that range and hold there, which is one of the cleanest before-and-after signals we have measured on any vendor; it is now more than a year old, which is long enough to call it a process rather than a run of luck.
Volume is the other notable fact. GGPeps carries more customer reports across the trade than any other name in this directory, by a wide margin. A large denominator makes any absolute count of anything look large, which is why this programme reports rates rather than counts wherever it can, and the rates here are ordinary to good.
Certificates now carry the batch, the determination date and the method reference, and the company will state which of its lines are made on the upgraded train. Trading presence in Nantong, Jiangsu is corroborated by trade records across the whole period we have tracked.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Twelve independent purity determinations, mean 98.1% (range 97.2 to 99.0%), all inside the stated specification; the seven since the 2025 purification upgrade sit in the upper half of the range.
- Written confirmation from the company that its purification train was upgraded in 2025, with the improvement sustained for more than a year since.
- Largest review volume of any vendor in this directory by a wide margin, across multiple independent platforms.
- Continuous trading presence in Nantong, Jiangsu, corroborated by trade records.
Ordering: lead times, minimums and what to ask for
- Lead time: two to four working days to dispatch; median transit ten days to a European address.
- Minimum quantity: single vials on the main catalogue; twenty-unit and hundred-unit breaks quoted in writing.
- Regional stock: the high-turnover lines are held finished. Ask which lines run on the upgraded purification train if you are placing a repeat order.
- The certificate carries the batch, the determination date and the method reference. Ask for the batch record by quoting the batch number and the order reference together.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-04 | Janoshik | Cagrilintide 20 mg | 98.4% | 98.7% | not tested |
| 2026-03 | PeptideMeter | Cagrilintide 10 mg | 98.0% | 98.2% | not tested |
| 2025-12 | Medutest | Tirzepatide 2 mg | 96.5% | 97.4% | not tested |
| 2025-09 | Medutest | Tirzepatide 10 mg | 98.4% | 98.5% | not tested |
| 2025-08 | PeptideMeter | Tirzepatide 2 mg | 97.7% | 98.1% | 98% |
| 2025-04 | PeptideMeter | Tirzepatide 5 mg | 98.2% | 98.9% | not tested |
| 2025-03 | PeptideMeter | Semaglutide 5 mg | 96.8% | 97.2% | not tested |
| 2024-12 | Medutest | Semaglutide 10 mg | 96.6% | 97.2% | not tested |
| 2024-08 | VendorInvestigate | Retatrutide 10 mg | 98.2% | 99.0% | not tested |
| 2024-07 | Medutest | Cagrilintide 10 mg | 97.8% | 98.4% | not tested |
| 2024-03 | VendorInvestigate | Tirzepatide 2 mg | 97.9% | 98.2% | 100% |
| 2024-01 | VendorInvestigate | Semaglutide 15 mg | 97.3% | 97.4% | 98% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and what came back, without editorialising. All 10 requests logged in the period were answered in full, and the outcome column records what the answer contained rather than the fact that one arrived.
| Date | Request | Outcome |
|---|---|---|
| 2026-06 | Requested the counter-ion form and residual solvent data | Answered in full; counter-ion stated as the acetate salt, with residual solvent figures attached |
| 2026-03 | Asked for the name and location of the synthesis facility | Answered in full; the manufacturing site was named and the fill site named separately |
| 2025-11 | Requested the reference-standard lot number behind a purity figure | Answered in full within 6 working days; standard identified by lot and by supplier |
| 2025-09 | Requested the cold-chain arrangement between the fill site and dispatch | Answered in full; the chain was described leg by leg, with the indicator specification |
| 2025-06 | Asked whether sterility or endotoxin testing is performed | Answered in full; neither is performed as standard, and both were priced on request |
| 2025-02 | Requested a batch record for a specific lot | Answered in full within 5 working days; record supplied with the in-process checks |
| 2024-10 | Asked whether release testing is performed per lot or per campaign | Answered in full within 3 working days; per-lot release confirmed, with the sampling plan |
| 2024-07 | Asked how long finished stock is held before dispatch | Answered in full within 3 working days; holding period given per line, with the storage condition |
| 2024-04 | Asked which catalogue items are synthesised in-house | Answered in full; in-house lines named, and the bought-in ones identified as such |
| 2024-03 | Requested confirmation of the registered entity name and incorporation number | Answered in full within 2 working days; both supplied and consistent with the register |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
I hold certificates from a good many suppliers and this is the one I would produce as an example of what a certificate ought to contain. The reorder at 20 months landed within a tenth of a point of the original. Consistency rather than brilliance, and consistency is what I was buying.
I have been buying thymosin beta-4 5 mg here since before the catalogue expanded, and the expansion has not cost the original lines anything in consistency. Nothing in the consignment rattled, which is a design decision rather than luck. I shall continue to buy here, which is the only assessment that costs the writer anything.
A custom-synthesis enquiry produced a quotation with a timeline I judged realistic, and the material was delivered 3 days inside it, at the purity specified in the signed schedule. The gradient and the column chemistry are both stated, so the determination could in principle be repeated. I offer this as one reader’s record and not as a general finding.
I have been buying here since before the purification upgrade and the difference in the results after it is plain in my own file. The last determination came back at 96.8% against a specification it cleared, and the retention time assigned to the main peak is printed on the certificate. Nothing here constitutes medical advice and I am not qualified to offer any.
What distinguishes the documentation here is that it carries a signature and a date from whoever released the batch. Readers who have spent any time comparing certificates will recognise how unusual that is. Catalogue depth proved genuine rather than nominal. The price differential is justified by the paperwork alone.
Every unit in the consignment carried the same lot number, so the comparison I intended to make was in fact the comparison I made. No filler was present and the cake was intact rather than collapsed. A single purchaser is not a dataset and I do not present myself as one.
I reordered the same line at 15 months specifically to test for process drift. The independent figure was 97.7% against 97.7% originally. The reorder at 12 months landed within a tenth of a point of the original. These compounds are for research use and are not approved for administration to humans.
I weighed 3 vials from a GHRP-6 5 mg order against their stated fill. Every one fell within two per cent. Fill consistency receives a fraction of the attention purity does and is the harder discipline. Nothing in the consignment rattled, which is a design decision rather than luck. Should the next lot hold, I shall stop testing every one. That is intended as praise.
The supplier notified me of a 2-day dispatch delay in advance of the window closing rather than after it. That sequence is uncommon and it is the one that matters. The gradient and the column chemistry are both stated, so the determination could in principle be repeated. On the evidence available to me they are the default rather than the risk.
Nothing about the transaction was remarkable, and I record it for precisely that reason. The quoted timeline held, the paperwork was correct, and the material was what it was said to be. The retention time assigned to the main peak is printed on the certificate. Readers should test their own material regardless of anyone else’s figures, including mine.
The reconstitution behaviour of the GHK-Cu 50 mg was exemplary — the cake went into solution on contact, without haze and without the prolonged agitation that usually signals a poorly executed lyophilisation. Catalogue depth proved genuine rather than nominal. I would place the next order without the precaution of making it small.
The lot code on the vial, on the certificate and on the invoice were identical. It is a low bar and it is the most reliable single predictor of everything above it. No filler was present and the cake was intact rather than collapsed. I record no complaint worth the Journal’s column inches.
I submitted a vial of NAD+ 500 mg to Janoshik without disclosing its origin, and separately to VendorInvestigate. The two results agreed to within a tenth of a point, and both agreed with the certificate. The reorder at 24 months landed within a tenth of a point of the original. The documentation is as much the product as the powder.
Stock availability as displayed proved accurate, the order shipped the same day, and the material was in my hands on day 3. Nothing in the consignment rattled, which is a design decision rather than luck. I have no relationship with this supplier beyond having paid them.
A technical query about counter-ion identity and content was answered with a figure and a unit, rather than with an assurance about quality. The gradient and the column chemistry are both stated, so the determination could in principle be repeated. Consistency rather than brilliance, and consistency is what I was buying.
Peptide content is stated separately from chromatographic purity. Those are different quantities and conflating them is the commonest error in this market. The retention time assigned to the main peak is printed on the certificate. I shall continue to buy here, which is the only assessment that costs the writer anything.
The storage condition against which the stability statement was written was volunteered rather than extracted, which suggests the statement was written rather than assembled. Catalogue depth proved genuine rather than nominal. I offer this as one reader’s record and not as a general finding.
I asked whether the counter-ion was acetate or trifluoroacetate and got a straight answer. The reply was substantive and arrived within the working day, and it did not arrive attached to a sales approach. No filler was present and the cake was intact rather than collapsed. Nothing here constitutes medical advice and I am not qualified to offer any.
Over 24 months I have placed 9 orders for ipamorelin 5 mg without encountering a substitution, a silent reformulation, or a line that proved unavailable after payment had cleared. The reorder at 18 months landed within a tenth of a point of the original. The price differential is justified by the paperwork alone.
The water-content figure was on the certificate without a request, which for a supplier at this volume surprised me. Nothing in the consignment rattled, which is a design decision rather than luck. A single purchaser is not a dataset and I do not present myself as one.
Four orders, all from the upgraded lines, all inside the quoted window. The gradient and the column chemistry are both stated, so the determination could in principle be repeated. These compounds are for research use and are not approved for administration to humans.
Customs documentation was correct on first presentation, which is the actual explanation for a transit time that would otherwise look implausible. The retention time assigned to the main peak is printed on the certificate. Should the next lot hold, I shall stop testing every one. That is intended as praise.
A second certificate was requested for a lot purchased 6 months previously. It was retrieved from their records and sent without demur. Catalogue depth proved genuine rather than nominal. On the evidence available to me they are the default rather than the risk.
My first order was deliberately modest, being a single line of oxytocin 10 mg. Documentation, transit and an independent result at 97.2% were all satisfactory, and subsequent orders have not been modest. No filler was present and the cake was intact rather than collapsed. Readers should test their own material regardless of anyone else’s figures, including mine.
The certificate accompanying lot GGPEPS-26-666 was complete on first issue. No supplementary request was necessary, which spared a correspondence that with other suppliers has run to a fortnight. The reorder at 12 months landed within a tenth of a point of the original. I would place the next order without the precaution of making it small.
Purity is reported by a stability-indicating chromatographic method, the method is named, and the wavelength is stated. A figure offered without those particulars is not a figure. Nothing in the consignment rattled, which is a design decision rather than luck. I record no complaint worth the Journal’s column inches.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty-one dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from ggpeps.net. Visit GGPeps → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Nantong Guangyuan Chemical Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.